Epygon, the developer of a new generation of transcatheter mitral valve has participated at PCR London Valve 2017, where the first presentation of its device has been made during Innovators Day.
Our Chief Medical Officer, Marcio Scorsin, explained in details how we can deal with patients with high mitral regurgitation.
The aim of Epygon project is to replace a transcatheter mitral bioprostheses as close as possible to the native valve from the anatomical and functional standpoint.
To deepen the topic click: